Skip to content
Screener

EPS (Diluted) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.23-4.5%
Opus Genetics logo
Opus GeneticsIRD
-$0.75-213%
Regenxbio logo
RegenxbioRGNX
$0.43+131%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$0.410.0%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
-$1.04-6.1%
Prime Medicine logo
Prime MedicinePRME
-$0.24+41.5%

Other financials

Income statement

See full
Revenue$321.4M+8,609%
Operating income$244.4M+646%
Net income$160.7M+514%

Balance sheet

See full
Cash & equivalents$143.2M+345%
Total debt$112.4M+39.6%
Total equity-$58.1M-276%
Total assets$396.4M+99.5%

Cash flow

See full
Operating cash flow-$38.5M+12.3%
CapEx$332.0K-73.1%
Free cash flow-$38.9M+14.0%

Valuation

See full
Market cap$1.02B+51.5%
Enterprise value$993.01M+47.1%
P/E40.8×—
P/S2.6×-22.1×

Profitability

See full
Operating margin-597.9%-207pp
Net margin-615.3%—
FCF margin-441.5%-126pp

Returns & leverage

See full
Return on equity-379.5%—
Debt / equity27.2×+26.1×
Current ratio3.8×+2.9×

Where this comes from

Reported directly by MeiraGTx Holdings plc in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: MeiraGTx Holdings plc’s 10-Q, filed August 13, 2026.

Filed
Aug 13, 2026, 8:23 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-095504
Line itemFor the Three-Month Periods Ended June 30, 2026For the Three-Month Periods Ended June 30, 2025For the Six-Month Periods Ended June 30, 2026For the Six-Month Periods Ended June 30, 2025
Foreign currency translation loss attributed to non-controlling interest(4)—(4)—
Comprehensive income (loss)$161,342$(41,254)$115,201$(82,582)
Net income (loss) per ordinary share:
Basic$1.76$(0.48)$1.32$(0.99)
Diluted$1.71$(0.48)$1.30$(0.99)
Weighted-average number of ordinary shares outstanding:
Basic91,418,52780,585,62586,387,68579,813,273
Diluted93,805,29680,585,62588,115,02379,813,273

Item 1. Financial Statements (Unaudited)

FAQ

What is MeiraGTx Holdings plc's EPS (diluted)?
MeiraGTx Holdings plc (MGTX) reported EPS (diluted) of $1.71 in Q2 2026.
How has MeiraGTx Holdings plc's EPS (diluted) changed year-over-year?
MeiraGTx Holdings plc's EPS (diluted) increased by 456.3% year-over-year, from -$0.48 to $1.71.
What is the long-term trend for MeiraGTx Holdings plc's EPS (diluted)?
Over 2 years (2021 to 2024), MeiraGTx Holdings plc's EPS (diluted) has grown at a 8.5% compound annual growth rate (CAGR), from -$1.81 to -$2.13.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about MeiraGTx Holdings plc's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude